| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.24B | 26.51B | 25.39B | 24.49B | 19.82B | 14.43B |
| Gross Profit | 17.11B | 16.81B | 16.05B | 15.59B | 12.28B | 8.49B |
| EBITDA | 6.60B | 6.55B | 6.18B | 6.10B | 4.71B | 2.61B |
| Net Income | 2.38B | 2.36B | 2.29B | 2.15B | 1.45B | 85.00M |
Balance Sheet | ||||||
| Total Assets | 61.93B | 64.26B | 60.52B | 60.56B | 59.41B | 52.32B |
| Cash, Cash Equivalents and Short-Term Investments | 2.79B | 2.25B | 2.56B | 1.96B | 3.29B | 8.93B |
| Total Debt | 14.05B | 13.22B | 11.66B | 12.20B | 13.02B | 11.89B |
| Total Liabilities | 23.52B | 23.26B | 21.63B | 22.41B | 23.54B | 19.52B |
| Stockholders Equity | 37.82B | 40.38B | 38.24B | 37.45B | 35.06B | 32.27B |
Cash Flow | ||||||
| Free Cash Flow | 3.36B | 3.35B | 3.33B | 3.21B | 3.52B | 2.30B |
| Operating Cash Flow | 4.91B | 4.87B | 4.86B | 4.78B | 4.54B | 2.95B |
| Investing Cash Flow | -3.69B | -3.62B | -1.72B | -2.62B | -8.06B | -480.00M |
| Financing Cash Flow | -359.00M | -1.65B | -2.42B | -3.58B | -2.04B | 1.50B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $168.32B | 64.18 | 6.01% | 1.23% | 6.06% | 3.53% | |
57 Neutral | $2.59B | ― | -2.67% | ― | 14.09% | 80.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $5.49B | ― | -4.22% | ― | 8.81% | 40.43% | |
45 Neutral | $2.62B | -2.76 | -37.78% | 4.88% | -5.78% | -445.83% |
EssilorLuxottica’s recent earnings call painted a predominantly positive picture, underscored by robust revenue growth and notable success in its direct-to-consumer and smart glasses segments. The company’s strategic focus on innovation and acquisitions has propelled its performance, despite facing challenges such as tariff impacts on gross margins and declines in e-commerce and department store sales. Overall, the positive developments significantly outweighed these challenges, setting a promising tone for the future.
EssilorLuxottica is a global leader in the design, manufacture, and distribution of advanced vision care products and eyewear, operating in the med-tech sector with a focus on innovation and sustainability. The company reported a 7.3% revenue growth in both Q2 and H1 2025, driven by strong performances across all regions and segments. Key highlights include a significant increase in sales of AI glasses, stable operating margins, and robust free cash flow generation. The acquisition of Optegra clinics marks a strategic step into the med-tech journey, enhancing the company’s comprehensive eyecare offerings. Looking forward, EssilorLuxottica remains committed to its growth targets and innovation in the eyewear and med-tech industry, aiming for mid-single-digit annual revenue growth and an adjusted operating profit margin of 19-20% by 2026.